Explore 3 Stock Ideas & Industry Insights Download Free Report

News

ADMA Biologics (NASDAQ:ADMA) Stock: Litigation Overhang Clouds a Profitable Business

ADMABiologicshas been one of the more talked-about names in the plasma-derived biologics space this year, but the conversation in September 2026 is less about growth and more about scrutiny. After a multi-year run that turned the Ramsey, New Jersey company into a profitable specialty-immunoglobulin …

Nitish Kishor | 10 September 2026

ADM Tronics (OTC:ADMT) Stock: A Sub-Penny Pop From an Actual Operating Business

A sharp percentage pop in a sub-penny stock always draws eyes, and ADM Tronics Unlimited (OTC:ADMT) is the latest to flash one. The New Jersey-based developer of medical devices and specialty chemistries trades far below a dollar, so even a fraction of a cent …

Nitish Kishor | 10 September 2026

ADVANTIS (OTC:ADVT) Hit by a Severe One-Day Drop: Is It Facing a Turning Point?

● ADVANTIS, trading under the ticker ADVT, sits at the extreme micro end of the market, with a quoted share price measured in fractions of a cent and aMarket Valuereported at less than $100,000.

Nitish Kishor | 10 September 2026

Aethlon Medical (NASDAQ: AEMD) Shares Drop: Why the Stock Is Under Pressure

Aethlon Medical, Inc. (NASDAQ: AEMD), a micro-cap medical-device developer, drew attention after its shares slid in a single session, according to market-data feeds. The move landed as the company continues to push its lead Hemopurifier device through an early-stage oncology study and shore up …

Nitish Kishor | 10 September 2026

Abeona Therapeutics (NASDAQ:ABEO) Shares Slip: What's Pressuring ABEO and What Comes Next?

● Abeona Therapeutics has completed one of the harder transitions in biotech: moving from a development-stage gene-therapy company to one with an approved product generating revenue.

Nitish Kishor | 10 September 2026

ABVC BioPharma (NASDAQ: ABVC) Shares Drop: Why the Stock Is Under Pressure

Volatility is a familiar feature for small clinical-stage drug developers, and ABVC BioPharma, Inc. (NASDAQ: ABVC) is no exception. The Nasdaq-listed biopharmaceutical company, which is advancing a spread of mid-stage candidates across cancer, neuropsychiatry and blood disorders, has seen its shares swing sharply this …

Nitish Kishor | 10 September 2026

Actuate Therapeutics (NASDAQ:ACTU) Stock: New Elraglusib Data Meets a Cash Runway Under Pressure

Actuate Therapeutics, Inc (NASDAQ:ACTU) presents an unusually stark contrast: encouraging new cancer data on one side, a looming cash crunch on the other. Just as the clinical-stage biotech published fresh preclinical results supporting its lead drug elraglusib, its own filings warned that cash could …

Nitish Kishor | 10 September 2026

AccuStem Sciences (OTC:ACUT) Stock: What's Behind the Diagnostics Nano-Cap's Recent Advance

A double-digit single-session gain in a stock as small as AccuStem Sciences Inc (OTC:ACUT) is easy to over-interpret. With aMarket Valueof only a few million dollars and a handful of employees, the shares can move sharply on very light volume.

Nitish Kishor | 10 September 2026

Adaptimmune (OTC:ADAPY) Stock: From FDA-Approved Pioneer to Penny-Priced OTC Name

Few recent stories in cell therapy have turned as sharply as Adaptimmune Therapeutics plc (OTC:ADAPY)'s. A company that in 2024 launched the first FDA-approved engineered T-cell receptor therapy for a solid tumor now trades for pennies on the over-the-counter market after a 2025 delisting …

Nitish Kishor | 10 September 2026

Invesco Senior Managing Director Sells Shares in Two Days

Andrew Tak Shing Lo, a Senior Managing Director at Invesco Ltd., filed a Form 4 on September 10, 2026, disclosing open market sales of common shares on September 8 and September 9, 2026.

Manish Choudhary | 10 September 2026
Support

Hi! How can we help you today?

Loading…